RT Journal Article
SR Electronic
T1 A statewide analysis of SARS-CoV-2 transmission in New York
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.02.20.21251598
DO 10.1101/2021.02.20.21251598
A1 Lasek-Nesselquist, Erica
A1 Singh, Navjot
A1 Russell, Alexis
A1 Lamson, Daryl
A1 Kelly, John
A1 Plitnick, Jonathan
A1 Pfeiffer, Ryan D.
A1 Tucker, Nathan
A1 Schneider, Erasmus
A1 George, Kirsten St.
YR 2021
UL http://medrxiv.org/content/early/2021/02/27/2021.02.20.21251598.abstract
AB New York State, in particular the New York City metropolitan area, was the early epicenter of the SARS-CoV-2 pandemic in the United States. Similar to initial pandemic dynamics in many metropolitan areas, multiple introductions from various locations appear to have contributed to the swell of positive cases. However, representation and analysis of samples from New York regions outside the greater New York City area were lacking, as were SARS-CoV-2 genomes from the earliest cases associated with the Westchester County outbreak, which represents the first outbreak recorded in New York State. The Wadsworth Center, the public health laboratory of New York State, sought to characterize the transmission dynamics of SARS-CoV-2 across the entire state of New York from March to September with the addition of over 600 genomes from under-sampled and previously unsampled New York counties and to more fully understand the breadth of the initial outbreak in Westchester County. Additional sequencing confirmed the dominance of B.1 and descendant lineages (collectively referred to as B.1.X) in New York State. Community structure, phylogenetic, and phylogeographic analyses suggested that the Westchester outbreak was associated with continued transmission of the virus throughout the state, even after travel restrictions and the on-pause measures of March, contributing to a substantial proportion of the B.1 transmission clusters as of September 30th, 2020.Competing Interest StatementThe authors have declared no competing interest.Funding StatementFunding was generously provided by the New York Community Trust.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This work was approved by the New York State Department of Health Institutional Review Board, under study numbers 02-054 and 07-022.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesSARS-CoV-2 genomes sequenced in this study have been deposited in GISAID.